Advertisement

Topics

OMEICOS Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial

05:00 EST 1 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Financing Provides Runway Beyond Completion of First-in-man Trial with Lead Compound OMT-28 for Treatment of Atrial Fibrillation OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule ther...

Other Sources for this Article

OMEICOS Therapeutics GmbH
Dr. Ulrich Dauer, +49 (0) 30 9489 4810
Chief Executive Officer and Managing Director
u.dauer@omeicos.com
or
Dr. Robert Fischer, +49 (0) 30 9489 4810
Chief Scientific Officer and Managing Director
r.fischer@omeicos.com
www.omeicos.com
or
Media requests:
MacDougall Biomedical Communications
Gretchen Schweitzer or Mario Brkulj, +49 (0) 89 2423 3494 or +49 175 5010575
mbrkulj@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "OMEICOS Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...